Company Registration No. 04725469 (England and Wales)
HEALTH DISPENSE LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
PAGES FOR FILING WITH REGISTRAR
King & King
Chartered Accountants
5th Floor
Watson House
54-60 Baker Street
London
W1U 7BU
HEALTH DISPENSE LIMITED
CONTENTS
Page
Accountants' report
1
Statement of financial position
2 - 3
Statement of changes in equity
4
Notes to the financial statements
5 - 13
HEALTH DISPENSE LIMITED
COMPANY INFORMATION
Directors
Mr R B Patel
Mrs J Patel
Mr H Shah
Secretary
Company number
04725469
Registered office
83-85 Baker Street
London
W1U 6AG
Accountants
King and King
83-85 Baker Street
London
W1U 6AG
Bankers
Lloyds Bank
1 Market Square
Aylesbury
Buckinghamshire
HP20 1TD
HEALTH DISPENSE LIMITED
ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF HEALTH DISPENSE LIMITED FOR THE YEAR ENDED 31 AUGUST 2025
- 1 -

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Health Dispense Limited for the year ended 31 August 2025 which comprise, the statement of financial position, the statement of changes in equity and the related notes from the company’s accounting records and from information and explanations you have given us.

 

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com/regulation.

This report is made solely to the board of directors of Health Dispense Limited, as a body, in accordance with the terms of the engagement letter dated 26 October 2018. Our work has been undertaken solely to prepare for your approval the financial statements of Health Dispense Limited and state those matters that we have agreed to state to the board of directors of Health Dispense Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Health Dispense Limited and its board of directors as a body, for our work or for this report.

It is your duty to ensure that Health Dispense Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Health Dispense Limited. You consider that Health Dispense Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Health Dispense Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

King and King
Chartered Accountants
83-85 Baker Street
London
W1U 6AG
21 May 2026
HEALTH DISPENSE LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
31 AUGUST 2025
31 August 2025
- 2 -
2025
2024
Notes
£
£
£
£
Non-current assets
Property, plant and equipment
4
119,452
132,412
Investments
5
40,100
40,100
159,552
172,512
Current assets
Inventories
290,282
287,408
Trade and other receivables
8
899,548
892,770
Cash and cash equivalents
440,388
314,552
1,630,218
1,494,730
Current liabilities
9
(1,038,391)
(1,018,112)
Net current assets
591,827
476,618
Total assets less current liabilities
751,379
649,130
Provisions for liabilities
10
(16,425)
(15,870)
Net assets
734,954
633,260
Equity
Called up share capital
11
100
100
Share premium account
99,900
99,900
Retained earnings
634,954
533,260
Total equity
734,954
633,260

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

For the financial year ended 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

 

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

HEALTH DISPENSE LIMITED
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT
31 AUGUST 2025
31 August 2025
- 3 -
The financial statements were approved by the board of directors and authorised for issue on 21 May 2026 and are signed on its behalf by:
Mr R B Patel
Director
Company Registration No. 04725469
HEALTH DISPENSE LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 AUGUST 2025
- 4 -
Share capital
Share premium account
Retained earnings
Total
Notes
£
£
£
£
Balance at 1 September 2023
100
99,900
457,911
557,911
Year ended 31 August 2024:
Profit and total comprehensive income for the year
-
-
162,569
162,569
Dividends
-
-
(87,220)
(87,220)
Balance at 31 August 2024
100
99,900
533,260
633,260
Year ended 31 August 2025:
Profit and total comprehensive income for the year
-
-
202,834
202,834
Dividends
-
-
(101,140)
(101,140)
Balance at 31 August 2025
100
99,900
634,954
734,954
HEALTH DISPENSE LIMITED
STATEMENT OF CHANGES IN EQUITY (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 5 -
1
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

2
Accounting policies
Company information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Roxburghe House, 273/287 Regent Street, London, W1B 2HA. The company registration number is 04725469.

2.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the company as an individual entity and not about its group.

 

2.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

2.3
Revenue

Revenue comprises sales of goods and services at invoice or reimbursement value less discounts and excluding value added tax.

 

Revenue from the provision of goods and all services is only recognised when the amounts to be recognised are fixed and determinable and collectability is reasonably assured.

 

Revenue from the provision of goods is recognised when the risks and rewards of ownership of goods have been transferred to the customer. The risks and rewards of ownership are deemed to have been transferred when the goods are delivered to, or are picked up by the customer.

 

HEALTH DISPENSE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2025
2
Accounting policies
(Continued)
- 6 -

The company recognises revenue from the following major sources:

 

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

Sale of goods

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Sale of services

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

 

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

2.4
Property, plant and equipment

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

 

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in equity, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in equity in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in equity in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Leasehold improvements
25% reducing balance
Fixtures and fittings
25% reducing balance
Motor vehicles
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

HEALTH DISPENSE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
2
Accounting policies
(Continued)
- 7 -
2.5
Non-current investments

Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.

 

Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.

 

Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses.

 

Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted.

 

Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.

2.6
Impairment of non-current assets

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

 

For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets.

 

For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

2.7
Inventories

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stock to its present location and condition.

2.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

HEALTH DISPENSE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
2
Accounting policies
(Continued)
- 8 -
2.9
Financial instruments

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

 

Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability.

 

Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.

2.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

2.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively.

 

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

 

Deferred tax

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

HEALTH DISPENSE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
2
Accounting policies
(Continued)
- 9 -
2.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or non-current assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

2.13
Retirement benefits

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund.

 

When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.

2.14
Leases
As lessee

Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.

2.15
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
24
26
HEALTH DISPENSE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 10 -
4
Property, plant and equipment
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 September 2024
263,373
560,957
824,330
Additions
-
0
26,857
26,857
At 31 August 2025
263,373
587,814
851,187
Depreciation and impairment
At 1 September 2024
223,775
468,143
691,918
Depreciation charged in the year
9,900
29,917
39,817
At 31 August 2025
233,675
498,060
731,735
Carrying amount
At 31 August 2025
29,698
89,754
119,452
At 31 August 2024
39,598
92,814
132,412
5
Fixed asset investments
2025
2024
£
£
Other investments other than loans
40,100
40,100
6
Subsidiaries

The company has taken advantage of the option not to prepare consolidated financial statement contained in Section 398 of the Companies Act 2006 on the basis that the company and its subsidiary undertakings comprise a small group.

Details of the company's subsidiaries at 31 August 2025 are as follows:

 

Health Dispense Property Limited

Name of undertaking
Registered office
Nature of business
Class of
% Held
shares held
Direct
Health Dispense Property Limited
83-85 Baker Street London W1U 6AG
Property Investment Company
Ordinary shares of £1 Each
100.00
The aggregate capital and reserves and the result for the year of the subsidiaries noted above was as follows:
Name of undertaking
Capital and Reserves
Profit/(Loss)
£
£
Health Dispense Property Limited
88,183
4,538
HEALTH DISPENSE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 11 -
7
Significant undertakings

The company also has significant holdings in undertakings which are not consolidated:

Name of undertaking
Registered office
Nature of business
Class of
% Held
shares held
Direct
Indirect
La Pharma Limited
England
Retail Pharmacy
Ordinary shares of £1 each
50.00
-
Valebret Limited
England
Retail Pharmacy
Ordinary shares of £1 each
-
50.00
The aggregate capital and reserves and the result for the year of significant undertakings noted above was as follows:
Name of undertaking
Profit/(Loss)
Capital and Reserves
£
£
8
Trade and other receivables
2025
2024
Amounts falling due within one year:
£
£
Trade receivables
190,993
204,060
Amounts owed by group undertakings
632,963
616,534
Other receivables
75,592
72,176
899,548
892,770
9
Current liabilities
2025
2024
£
£
Trade payables
669,699
715,580
Amounts owed to group undertakings and undertakings in which the company has a participating interest
221,095
207,095
Corporation tax
100,988
57,149
Other taxation and social security
8,487
6,546
Other payables
38,122
31,742
1,038,391
1,018,112
HEALTH DISPENSE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
- 12 -
10
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the company:

Liabilities
Liabilities
2025
2024
Balances:
£
£
Accelerated capital allowances
16,425
15,870
2025
Movements in the year:
£
Liability at 1 September 2024
15,870
Charge to profit or loss
555
Liability at 31 August 2025
16,425

The deferred tax liability set out above is expected to reverse within [12 months] and relates to accelerated capital allowances that are expected to mature within the same period.

11
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary A shares of £1 each
70
70
70
70
Ordinary B shares of £1 each
30
30
30
30
100
100
100
100
12
Operating lease commitments
As lessee

 

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2025
2024
£
£
Total commitments
560,000
630,000
13
Directors' transactions

Dividends totalling £0 (2024 - £87,220) were paid in the year in respect of shares held by the company's directors.

14
Related party transactions
HEALTH DISPENSE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2025
14
Related party transactions
(Continued)
- 13 -
Sales
Purchases
2025
2024
2025
2024
£
£
£
£
Entities with control, joint control or significant influence over the company
24,009
14,626
19,558
6,285
Entities over which the entity has control, joint control or significant influence
322
-
0
3,827
10,083
Loan
2025
2024
£
£
(14,000)
(58,000)
2025
2024
Amounts due to related parties
£
£
Entities with control, joint control or significant influence over the company
511,171
497,414
2025
2024
Amounts due from related parties
£
£
Entities with control, joint control or significant influence over the company
632,963
616,533

The Company has taken advantage of the exemptions available under FRS 102 Section 33.1A and as a results has not disclosed within the financial statements’ details of transactions with group members, undertaken during the year.

 

15
Controlling party

The company was under the control of Mr R B Patel and Mrs J R Patel throughout the current and previous year. Mr R B Patel and Mrs J R Patel are the majority shareholders.

2025-08-312024-09-01falsefalsefalse21 May 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityMr R B PatelMrs J PatelMr H Shah047254692024-09-012025-08-3104725469bus:Director12024-09-012025-08-3104725469bus:Director22024-09-012025-08-3104725469bus:Director32024-09-012025-08-3104725469bus:RegisteredOffice2024-09-012025-08-3104725469bus:Agent12024-09-012025-08-31047254692025-08-31047254692024-08-3104725469core:LandBuildings2025-08-3104725469core:OtherPropertyPlantEquipment2025-08-3104725469core:LandBuildings2024-08-3104725469core:OtherPropertyPlantEquipment2024-08-3104725469core:CurrentFinancialInstrumentscore:WithinOneYear2025-08-3104725469core:CurrentFinancialInstrumentscore:WithinOneYear2024-08-3104725469core:CurrentFinancialInstruments2025-08-3104725469core:CurrentFinancialInstruments2024-08-3104725469core:ShareCapital2025-08-3104725469core:ShareCapital2024-08-3104725469core:SharePremium2025-08-3104725469core:SharePremium2024-08-3104725469core:RetainedEarningsAccumulatedLosses2025-08-3104725469core:RetainedEarningsAccumulatedLosses2024-08-3104725469core:ShareCapital2023-08-3104725469core:SharePremium2023-08-3104725469core:RetainedEarningsAccumulatedLosses2023-08-31047254692023-08-3104725469core:ShareCapitalOrdinaryShareClass12025-08-3104725469core:ShareCapitalOrdinaryShareClass12024-08-3104725469core:ShareCapitalOrdinaryShareClass22025-08-3104725469core:ShareCapitalOrdinaryShareClass22024-08-3104725469core:ShareCapitalOrdinaryShares2025-08-3104725469core:ShareCapitalOrdinaryShares2024-08-3104725469core:RetainedEarningsAccumulatedLosses2023-09-012024-08-31047254692023-09-012024-08-3104725469core:RetainedEarningsAccumulatedLosses2024-09-012025-08-3104725469core:LeaseholdImprovements2024-09-012025-08-3104725469core:FurnitureFittings2024-09-012025-08-3104725469core:MotorVehicles2024-09-012025-08-3104725469core:LandBuildings2024-08-3104725469core:OtherPropertyPlantEquipment2024-08-31047254692024-08-3104725469core:LandBuildings2024-09-012025-08-3104725469core:OtherPropertyPlantEquipment2024-09-012025-08-3104725469core:Subsidiary12024-09-012025-08-3104725469core:Subsidiary112024-09-012025-08-3104725469core:Subsidiary12025-08-3104725469bus:OrdinaryShareClass12024-09-012025-08-3104725469bus:OrdinaryShareClass22024-09-012025-08-3104725469bus:OrdinaryShareClass12025-08-3104725469bus:OrdinaryShareClass12024-08-3104725469bus:OrdinaryShareClass22025-08-3104725469bus:OrdinaryShareClass22024-08-3104725469bus:AllOrdinaryShares2025-08-3104725469bus:AllOrdinaryShares2024-08-3104725469core:EntitiesWithJointControlOrSignificantInfluenceOverReportingEntitycore:SaleOrPurchaseGoods2024-09-012025-08-3104725469core:EntitiesWithJointControlOrSignificantInfluenceOverReportingEntitycore:SaleOrPurchaseGoods2023-09-012024-08-3104725469core:AllSubsidiariescore:SaleOrPurchaseGoods2024-09-012025-08-3104725469core:AllSubsidiariescore:SaleOrPurchasePropertyOrOtherAssets2023-09-012024-08-3104725469core:EntitiesWithJointControlOrSignificantInfluenceOverReportingEntity2025-08-3104725469bus:PrivateLimitedCompanyLtd2024-09-012025-08-3104725469bus:SmallCompaniesRegimeForAccounts2024-09-012025-08-3104725469bus:FRS1022024-09-012025-08-3104725469bus:AuditExemptWithAccountantsReport2024-09-012025-08-3104725469bus:FullAccounts2024-09-012025-08-31xbrli:purexbrli:sharesiso4217:GBP